ARTICLE
Guidelines for the use of second-generation long-acting antipsychotics
More details
Hide details
1
III Klinika Psychiatryczna Instytutu Psychiatrii i Neurologii w Warszawie
2
III Klinika Psychiatryczna Instytutu Psychiatrii i Neurologii
3
Zakład Zaburzeń Afektywnych Katedry Psychiatrii, UJ Collegium Medicum
4
Klinika Psychiatrii Pomorskiego Uniwersytetu Medycznego w Szczecinie
5
Zakład Farmakologii Instytutu Psychiatrii i Neurologii w Warszawie
6
Klinika Psychiatrii Dorosłych Uniwersytetu Medycznego im. K. Marcinkowskiego w Poznaniu
Submission date: 2014-12-12
Final revision date: 2015-02-26
Acceptance date: 2015-02-26
Publication date: 2015-04-30
Corresponding author
Marek Jarema
III Klinika Psychiatryczna Instytutu Psychiatrii i Neurologii w Warszawie, Sobieskiego 9, 02-957 Warszawa, Polska
Psychiatr Pol 2015;49(2):225-241
KEYWORDS
TOPICS
ABSTRACT
Long-acting injectable antipsychotics constitute a valuable alternative for the treatment of psychotic disorders, mainly schizophrenia. They assure a more stable drug level, improve treatment compliance, and increase the chances for favorable and long-lasting improvement. Additionally, the long-acting second-generation antipsychotics combine the values of long-acting injectable drugs with the values of atypical antipsychotics. Four second generation long-acting antipsychotics have been described: risperidone, olanzapine, aripiprazole and paliperidone. The indications for their use, treatment strategy, tolerance, and potential interactions are discussed.